Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 26

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 26
---
 the
issuance and sale of our common stock and warrants in the January 2025 Financing, the issuance and sale of our common stock under the
SEPA and the issuance of convertible notes and warrants in the June 2025 Financing. Net cash provided by financing activities for the
six months ended June 30, 2024 was approximately $0.4 million, which was provided by issuance and sale of our common stock under the
ATM Agreement.

6

Funding
Requirements

Our
operating expenses are expected to continue to increase in the future in connection with our ongoing activities, particularly as we expect
to continue to ramp up our clinical development activities and incur expenses associated with hiring additional personnel to support
our research and development efforts. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur
significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we expect to
continue to incur significant costs associated with operating as a public company.

We
believe that our existing cash and cash equivalents as of June 30, 2025 are adequate to fund our ongoing activities into the fourth
quarter of 2025 based on our current operating plan. In addition, in May 2025, we began implementing a cost-reduction plan that included a focus on the Combination
Study, the elimination of non-essential expenses, and accepted a voluntary temporary reduction of the base salaries of certain
officers and temporary elimination of board fees.

Our
future capital requirements will depend on many factors, including, but not limited to:

    ●
    the
    scope, progress, results and costs of preclinical studies and clinical trials;

    ●
    the
    scope, prioritization and number of our clinical trials and other research and development programs;

    ●
    the
    amount of revenues we receive under future licensing, collaboration, development and commercialization arrangements with respect
    to our product candidates;

    ●
    the
    impact of any pandemic, epidemic or other future health crisis on our business and operations;

    ●
    the
    costs of the development and expansion of our operational infrastructure;

    ●
    the
    costs, timing and outcome of regulatory review of our product candidates;

    ●
    the
    ability of us, or our collaborators, to achieve development milestones, marketing approval and other events or developments under
    our potential future licensing